China-based, TenNor, a healthcare company that develops new therapies for infectious diseases at its clinical stage raised 300 million Yuan in Series E round.
Zhongshan Venture Capital, and AMR Action Fund among some existing investors actively backed the round.
China’s TenNor Raised $41M
CEO TenNor, Dr. Zhenkun Ma said that funds raised will help them with regulations and approval in China. This new drug rifasutenizol is specifically made for Helicobacter pylori infection.
TenNor Therapeutics is a healthcare company that is at the clinical stage and developing a new drug against Helicobacter pylori infection and other infectious diseases. TenNor is working on new drug trials and regulations. Their many products are in the last stage of development targeting bacterial infection, pylori infection, IBS, and diarrhea.
Also Read: Company Details